Expression of 34β E 12 in prostatic lesion
Abstract
Introduction: Prostate cancer is the second most common cause of cancer and the sixth leading cause of cancer death among men worldwide, To diagnose prostate cancer, no specific single histologic feature is sufficiently available. It is a challenging task to accurately diagnose small foci of prostate cancer for pathologists and to distinguish cancer from its benign mimickers.
Material and Methods: The present study was a prospective study. Establishing a definitive diagnosis of malignancy in prostate needle biopsies with very little foci of adenocarcinoma is a major diagnostic challenge for pathologists. A negative diagnostic marker specific for prostatic adenocarcinoma may enhance the ability to detect limited prostate cancer and reduce errors in diagnosis. The recent discovery of the 34βE12 in prostate cancer is a successful example of translating an advanced molecular finding into clinical practice.
Results: Among 37 cases 19 were prostatic cancer, 5 were prostatic intraepithelial neoplasia, 1 case was atypical foci, and 9 were benign prostatic hyperplasia cases. 34βE12has been proven to be one of the few biomarkers that can help distinguish cancer from benign cells, with high sensitivity and specificity for prostate carcinoma. This study focuses on the study of 34βE12 expression in prostate cancer, premalignant lesions, benign prostate tissues, and other normal and malignant tissues and a discussion of its clinical usefulness.
Conclusion: The present study recommends the interpretation of the 34βE12 immunohistochemical results in routine surgical pathology practice and also discuss the potential future applications of this marker in diagnosis of various lesions.
Downloads
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Can J Clinic. 2018;68(6):394-424. doi: https://doi.org/10.3322/caac.21492.
Shewale JB, Gillison ML. Dynamic factors affecting HPV-attributable fraction for head and neck cancers. Curr Op Virol. 2019;39:33-40. doi: https://doi.org/10.1016/j.coviro.2019.07.008.
Kunju LP, Rubin MA, Chinnaiyan AM, Shah RB. Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. Am J Clinic Pathol. 2003;120(5):737-745. doi: https://doi.org/10.1309/3T3Y0K0TUMYH3WY2.
Oppenheimer JR, Wills ML, Epstein JI. Partial atrophy in prostate needle cores: another diagnostic pitfall for the surgical pathologist. Am J Surg Pathol. 1998;22(4):440-445. doi: https://doi.org/10.1097/00000478-199804000-00008.
Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA: Can J Clinic. 1999;49(1):8-31. doi: https://doi.org/10.3322/canjclin.49.1.8.
DiGiuseppe JA, Sauvageot J, Epstein JI. Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol. 1997;21(2):174-178. doi: https://doi.org/10.1097/00000478-199702000-00006.
Epstein JI. Diagnostic criteria of limited adenocarcinoma of the prostate on needle biopsy. Human Pathol. 1995;26(2):223-229. doi: https://doi.org/10.1016/0046-8177(95)90041-1.
Algaba F, Epstein JI, Aldape HC, Farrow GM, Lopez-Beltran A, Maksem J, Orozco RE, Pacelli A, Pisansky TM, Trias I. Workgroup 5: Assessment of prostate carcinoma in core needle biopsy-definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer. 1996;78(2):376-381. doi: https://doi.org/10.1002/(SICI)1097-0142(19960715)78:2<376::AID-CNCR32>3.0.CO;2-R.
Thorson P, Humphrey PA. Minimal adenocarcinoma in prostate needle biopsy tissue. Am J Clinic Pathol. 2000;114(6):896-909. doi: https://doi.org/10.1309/KVPX-C1EM-142L-1M6W.
Catalona WJ, Richie JP, Ahmann FR, Hudson ML, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151(5):1283-1290. doi: https://doi.org/10.1016/S0022-5347(17)35233-3.
Epstein JI, Potter SR. The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies. J Urol. 2001;166(2):402-410. doi: https://doi.org/10.1016/S0022-5347(05)65953-8.
Beach R, Gown AM, De Peralta-Venturina MN, Folpe AL, Yaziji H, Salles PG, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002;26(12):1588-1596. doi : https://doi.org/10.1097/00000478-200212000-00006.
Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31(1):11-24. doi: https://doi.org/10.1016/0092-8674(82)90400-7.
Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol. 1989;13(5):389-396. doi: https://doi.org/10.1097/00000478-198905000-00006.
Mehta R, Jain RK, Sneige N, Badve S, Resetkova E. Expression of high-molecular-weight cytokeratin (34βE12) is an independent predictor of disease-free survival in patients with triple-negative tumours of the breast. J Clinic Pathol. 2010;63(8):744-747. doi : http://dx.doi.org/10.1136/jcp.2010.076653.
Sturm N, Rossi G, Lantuejoul S, Laverrière MH, Papotti M, Brichon PY, et al. 34βE12 expression along the whole spectrum of neuroendocrine proliferations of the lung, from neuroendocrine cell hyperplasia to small cell carcinoma. Histopathol. 2003;42(2):156-166. doi: https://doi.org/10.1046/j.1365-2559.2003.01541.x.
Aishima SI, Asayama Y, Taguchi KI, Sugimachi K, Shirabe K, Shimada M, et al. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma. Mod Pathol. 2002;15(11):1181. doi: https://doi.org/10.1097/01.MP.0000032537.82380.69.
Kumaresan K, Kakkar N, Verma A, Mandal AK, Singh SK, Joshi K. Diagnostic utility of α-methylacyl CoA racemase (P504S) & HMWCK in morphologically difficult prostate cancer. Diagnos Pathol. 2010;5(1):83. doi: https://doi.org/10.1186/1746-1596-5-83.
OAI - Open Archives Initiative
